Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy

Background: Breast cancer is the most common form of cancer in women worldwide. Advances in the early diagnosis and treatment of cancer in the last decade have progressively decreased the cancer mortality rate, and in recent years, immunotherapy has emerged as a relevant tool against cancer. HER2+ a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolini, Andrea, Ferrari, Paola, Carpi, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599105/
https://www.ncbi.nlm.nih.gov/pubmed/36289773
http://dx.doi.org/10.3390/biomedicines10102511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599105/
https://www.ncbi.nlm.nih.gov/pubmed/36289773
http://dx.doi.org/10.3390/biomedicines10102511

Ejemplares similares